Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16339089 | 0.81 | POLB (0.38) | KDM4ENOTUMALDH1A1HSD17B10KIT | |
| SCHEMBL16340074 | 0.80 | KMT2A (0.40) | KDM4EHPGDMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL16339725 | 0.77 | EGFR (0.42) | MAPK1EGFR | |
| SCHEMBL16374339 | 0.73 | MTOR (0.36) | MAPK1EGFR | |
| SCHEMBL16339495 | 0.73 | EGFR (0.75) | EGFR | |
| SCHEMBL16339091 | 0.70 | EGFR (0.35) | KDM4EHPGDALDH1A1EGFR | |
| SCHEMBL31539675 | 0.69 | LMNA (0.36) | KDM4EMAPK1L3MBTL1EGFR | |
| SCHEMBL16339483 | 0.69 | MAPK1 (0.34) | MAPK1EGFR | |
| SCHEMBL16339511 | 0.69 | EGFR (0.38) | EGFR | |
| SCHEMBL16339509 | 0.69 | EGFR (0.38) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052494-B1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3052494-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | KDM4E 1782/4885HPGD 3904/4885MAPK1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.